Mostrar el registro sencillo del ítem

dc.contributor.authorPardo Moreno, Teresa
dc.contributor.authorGónzalez Acedo, Anabel 
dc.contributor.authorRivas Domínguez, Antonio
dc.contributor.authorGarcía-Morales, Victoria
dc.contributor.authorGarcía-Cozar, Francisco Jose
dc.contributor.authorRamos Rodríguez, Juan José 
dc.contributor.authorMelguizo-Rodríguez, Lucía
dc.date.accessioned2024-09-16T08:52:40Z
dc.date.available2024-09-16T08:52:40Z
dc.date.issued2022-05-24
dc.identifier.citationPardo Moreno, T. et. al. Pharmaceutics 2022, 14, 1117. [https://doi.org/10.3390/pharmaceutics14061117]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/94467
dc.description.abstractAlzheimer’s disease (AD) is the most common cause of dementia. The pathophysiology of this disease is characterized by the accumulation of amyloid- , leading to the formation of senile plaques, and by the intracellular presence of neurofibrillary tangles based on hyperphosphorylated tau protein. In the therapeutic approach to AD, we can identify three important fronts: the approved drugs currently available for the treatment of the disease, which include aducanumab, donepezil, galantamine, rivastigmine, memantine, and a combination of memantine and donepezil; therapies under investigation that work mainly on A pathology and tau pathology, and which include -secretase inhibitors, -secretase inhibitors, -secretase modulators, aggregation inhibitors, metal interfering drugs, drugs that enhance A clearance, inhibitors of tau protein hyperphosphorylation, tau protein aggregation inhibitors, and drugs that promote the clearance of tau, and finally, other alternative therapies designed to improve lifestyle, thus contributing to the prevention of the disease. Therefore, the aim of this review was to analyze and describe current treatments and possible future alternatives in the therapeutic approach to AD.es_ES
dc.description.sponsorshipP20-01293 from Junta de Andalucía, Spain, PECART-0096- 2020 from Junta de Andalucía, Spaines_ES
dc.description.sponsorshipPID2020-117544RB-100 from the Ministry of Science and Innovation, Spaines_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAlzheimer’s diseasees_ES
dc.subjectdementia es_ES
dc.subjectA pathologyes_ES
dc.titleTherapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectiveses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/pharmaceutics14061117
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional